The prevalence of ataxia telangiectasia mutated (ATM) variants in patients with breast cancer patients: a systematic review and meta-analysis

Abstract

Breast cancer is the most common cancer in women, and its high mortality has become one of the biggest health problems globally. Several studies have reported an association between breast cancer and ATM gene variants. This study aimed to demonstrate and analyze the relationship between ATM gene polymorphisms and breast cancer prevalence rate. A systematic literature review was undertaken using the following databases: Medline (PubMed), Web of sciences, Scopus, EMBASE, Cochrane, Ovid, and CINHAL to retrieve all cross-sectional studies between January 1990 and January 2020, which had reported the frequency of ATM variants in patients with breast cancer. A random-effects model was applied to calculate the pooled prevalence with a 95 confidence interval. The pooled prevalence of ATM variants in patients with breast cancer was 7 (95 CI: 5-8). Also, the pooled estimate based on type of variants was 6 (95 CI: 4-8; I square: 94; P: 0.00) for total variants, 0 (95 CI: 0-1; I square: 0; P: 0.59) for deletion variants, 12 (95 CI: 7-18; I square: 99; P: 0.00) for substitution variants, and 2 (95 CI: 4-9; I square: 67; P: 0.08) for insertion variants. This meta-analysis showed that there is a significant relationship between ATM variants in breast cancer patients. Further studies are required to determine which of the variants of the ATM gene are associated with BRCA mutations.